Precision BioSciences director Raymond Schinazi resigns from board, stays on SAB

PRECISION BIOSCIENCES INC

Dr. Raymond Schinazi resigned from the Board effective Nov 5, 2022.
He stepped down as Chair of Nominating and Governance Committee and from Compensation and Science/Technology Committees.
Schinazi will continue serving on the company's Scientific Advisory Board.
No successor named; Board plans to refresh with new independent directors.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Raymond Schinazi

Director

DTIL · PRECISION BIOSCIENCES INC

Effective: 2022-11-05
Filed: November 10, 2022, 6:59 PM ET

On November 5, 2022, Dr. Raymond Schinazi informed the Board of Directors (the 'Board') of Precision BioSciences, Inc. (the 'Company' or 'Precision') that he was resigning from the Board, as well as his roles as Chair of the Board’s Nominating and Corporate Governance Committee and a member of the Board’s Compensation Committee and Science and Technology Committee, with immediate effect.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Raymond Schinazi resigned as Director at PRECISION BIOSCIENCES INC.

Action: resigned
Role: Director

Exact text from the filing

On November 5, 2022, Dr. Raymond Schinazi informed the Board of Directors (the 'Board') of Precision BioSciences, Inc. (the 'Company' or 'Precision') that he was resigning from the Board, as well as his roles as Chair of the Board’s Nominating and Corporate Governance Committee and a member of the Board’s Compensation Committee and Science and Technology Committee, with immediate effect.

View on SEC.gov

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0000950170-22-024562

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.